[go: up one dir, main page]

PE20170184A1 - Derivados de piperidina como antagonista de receptores de orexina - Google Patents

Derivados de piperidina como antagonista de receptores de orexina

Info

Publication number
PE20170184A1
PE20170184A1 PE2016001578A PE2016001578A PE20170184A1 PE 20170184 A1 PE20170184 A1 PE 20170184A1 PE 2016001578 A PE2016001578 A PE 2016001578A PE 2016001578 A PE2016001578 A PE 2016001578A PE 20170184 A1 PE20170184 A1 PE 20170184A1
Authority
PE
Peru
Prior art keywords
optionally substituted
substituted
orexin receptors
antagonist
compounds
Prior art date
Application number
PE2016001578A
Other languages
English (en)
Inventor
Shuhui Chen
Yuan Chen
Haiying He
Jiong Lan
Yang Zhang
Qiang Lv
Biao Ma
Yuhe Wang
Songliang Wu
Xing Liu
Original Assignee
Shanghai Haiyan Pharmaceutical Tech Co Ltd
Yangtze River Pharm Group Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54054589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170184(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shanghai Haiyan Pharmaceutical Tech Co Ltd, Yangtze River Pharm Group Co filed Critical Shanghai Haiyan Pharmaceutical Tech Co Ltd
Publication of PE20170184A1 publication Critical patent/PE20170184A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIPERIDINA DE FORMULA (I) DONDE A ES UN CICLOHIDROCARBILO, HETEROCICLOHIDROCARBILO O HETEROHIDROCARBILO CICLICO DE 3 A 12 MIEMBROS OPCIONALMENTE SUSTITUIDO; B ES C(=O), S(=O) O S(=O)2; X ES (CH2)r1(U)r2(CH2)r3 OPCIONALMENTE SUSTITUIDO, EN DONDE U ES HALOGENO, HIDROXI, ALQUILO C1-6, ENTRE OTROS; D Y L SON CADA UNO CH2 OPCIONALMENTE SUSTITUIDO CON F, Br, CN, ENTRE OTROS; T ES C O UN ENLACE; CUANDO M ES C(Y)(R1a) Q ES C(R1b)(R1c) Y VICEVERSA, EN DONDE Y ES (CH2)r4(G)r5(CH2)r6-Y1; Y1 es O-E, ENTRE OTROS, EN DONDE E ES CICLOHIDROCARBILO O HETEROCICLO DE 5 A 6 MIEMBROS OPCIONALMENTE SUSTITUIDO; G ES HALOGENO SUSTITUIDO, HIDROXI SUSTITUIDO, ENTRE OTROS; r1, r3, r4 y r6 SON DE 0 A 2; r2 y r5 SON 0 O 1; R1a, R1b, R1c, R2 y R3 SON CADA UNO H, F, CN, NH2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS LOS DE FORMULA (i), (ii), ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE RECEPTORES DE OREXINA SIENDO UTILES EN EL TRATAMIENTO DE INSOMNIO, ANSIEDAD, TRASTORNO OBSESIVO-COMPULSIVO
PE2016001578A 2014-03-06 2015-02-27 Derivados de piperidina como antagonista de receptores de orexina PE20170184A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410081220 2014-03-06

Publications (1)

Publication Number Publication Date
PE20170184A1 true PE20170184A1 (es) 2017-04-07

Family

ID=54054589

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001578A PE20170184A1 (es) 2014-03-06 2015-02-27 Derivados de piperidina como antagonista de receptores de orexina

Country Status (16)

Country Link
US (1) US10100047B2 (es)
EP (1) EP3115362B1 (es)
JP (1) JP6262885B2 (es)
KR (1) KR101920472B1 (es)
CN (1) CN106414439B (es)
AU (1) AU2015226679B2 (es)
CA (1) CA2941663C (es)
CL (1) CL2016002240A1 (es)
IL (1) IL247584A0 (es)
MX (1) MX2016011549A (es)
NZ (1) NZ723671A (es)
PE (1) PE20170184A1 (es)
RU (1) RU2669701C2 (es)
SG (2) SG10201900536TA (es)
WO (1) WO2015131773A1 (es)
ZA (1) ZA201606141B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2852054T3 (es) 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2017012502A1 (en) 2015-07-17 2017-01-26 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
CN111499625B (zh) 2015-08-14 2022-09-02 上海海雁医药科技有限公司 食欲素受体拮抗剂受体化合物的制备方法及其中间体和晶型
JP6936224B2 (ja) 2015-11-23 2021-09-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． オクタヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用
US10508083B2 (en) 2016-02-04 2019-12-17 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
KR102876124B1 (ko) * 2020-04-17 2025-10-24 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 고형 약물 제제 및 이의 제조 방법과 용도
CN112480107B (zh) * 2020-11-30 2022-08-16 上海海雁医药科技有限公司 取代的氮杂双环辛烷化合物及其中间体和制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2525124A1 (en) * 2003-05-13 2004-11-25 Schering Corporation Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
US20090247499A1 (en) * 2006-08-21 2009-10-01 Fletcher Joan M Sulfonylated piperazines as cannabinoid-1 receptor modulators
CA2688776A1 (en) * 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
EP2150115B1 (en) * 2007-05-23 2013-09-18 Merck Sharp & Dohme Corp. Cyclopropyl pyrrolidine orexin receptor antagonists
WO2008147518A1 (en) * 2007-05-23 2008-12-04 Merck & Co., Inc. Pyridyl piperidine orexin receptor antagonists
AU2009211724B2 (en) * 2008-02-06 2013-05-16 Msd K.K. 3-substituted sulfonyl piperazine derivative
CN101965343A (zh) 2008-02-21 2011-02-02 埃科特莱茵药品有限公司 2-氮杂-双环[2.2.1]庚烷衍生物
JP2012506374A (ja) * 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
EP2348856B1 (en) * 2008-10-21 2013-08-14 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
CA2739916A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010048016A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
JP5899202B2 (ja) * 2010-04-29 2016-04-06 ザ ユニバーシティ オブ エディンバラ １１β−ＨＳＤ１の阻害剤としての３，３−二置換−（８−アザ−ビシクロ［３．２．１］オクタ−８−イル）−［５−（１Ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン類
AU2011283684B2 (en) * 2010-07-29 2015-08-27 Rigel Pharmaceuticals, Inc. AMPK-activating heterocyclic compounds and methods for using the same
WO2013005755A1 (ja) * 2011-07-05 2013-01-10 大正製薬株式会社 メチルピペリジン誘導体
AR088352A1 (es) * 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
TW201326151A (zh) * 2011-10-25 2013-07-01 Shionogi & Co 具有ｐｇｄ２受體拮抗活性之雜環衍生物
JOP20130213B1 (ar) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
AU2013347538B2 (en) * 2012-11-16 2017-04-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
TWI621618B (zh) * 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途

Also Published As

Publication number Publication date
AU2015226679B2 (en) 2017-05-25
AU2015226679A1 (en) 2016-09-15
KR20160143668A (ko) 2016-12-14
CA2941663A1 (en) 2015-09-11
MX2016011549A (es) 2017-05-08
EP3115362A4 (en) 2017-08-16
JP6262885B2 (ja) 2018-01-17
NZ723671A (en) 2017-05-26
CN106414439B (zh) 2017-12-08
CL2016002240A1 (es) 2017-02-17
EP3115362B1 (en) 2019-06-12
KR101920472B1 (ko) 2019-02-08
IL247584A0 (en) 2016-11-30
SG11201607183PA (en) 2016-10-28
RU2669701C2 (ru) 2018-10-15
CN106414439A (zh) 2017-02-15
US20170233385A1 (en) 2017-08-17
ZA201606141B (en) 2017-05-31
US10100047B2 (en) 2018-10-16
JP2017507185A (ja) 2017-03-16
RU2016130937A (ru) 2018-04-09
EP3115362A1 (en) 2017-01-11
WO2015131773A1 (zh) 2015-09-11
CA2941663C (en) 2020-02-18
SG10201900536TA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
PE20170184A1 (es) Derivados de piperidina como antagonista de receptores de orexina
CL2017002452A1 (es) Nuevos compuestos bicíclicos
ECSP18053053A (es) Conjugado persistente de triple activador que activa el receptor de glucagón, GLP-1 u GIP
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
MX385424B (es) Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
EP3654978A4 (en) HETEROCYCLIC COMPOUNDS USED AS ADENOSINE ANTAGONISTS
AR099677A1 (es) Compuesto heterocíclico fusionado y su uso para el control de plagas
PE20190509A1 (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
MX2018000880A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
PE20180483A1 (es) Oxiesteroles y metodos de uso de los mismos
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
AR100154A1 (es) Compuesto heterocíclico que contiene nitrógeno
PE20170144A1 (es) 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet
CL2015002609A1 (es) 2-azabiciclos sustituidos y su uso como moduladores de rectores de orexina.
CR20110049A (es) Derivados de benzazepina y su uso como antagonistas de histamina h3
PE20161572A1 (es) Compuestos como moduladores de ror gamma
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
EA201592082A1 (ru) 3,4-дигидроизохинолин-2(1h)-ильные соединения
CY1119583T1 (el) Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα
EP3826990A4 (en) COMPOUNDS FOR USE AS NEUROKININ-1 RECEPTOR ANTAGONISTS AND THEIR USES
MX2016011380A (es) Derivados de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona y su uso como agentes antibacterianos.
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c&#39;] dipyrrol-2-yl

Legal Events

Date Code Title Description
FD Application declared void or lapsed